A trial of oral azacitidine for acute myeloid leukaemia that has completely disappeared after chemotherapy (QUAZAR AML-001)
Cancer type:
Status:
Phase:
This trial looked azacitidine tablets and best supportive care for acute myeloid leukaemia that was in remission. This means people had no signs of leukaemia after initial treatment.
The trial was open for people to join between 2013 and 2017. The team published the results in 2020. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Doctors usually treat acute myeloid leukaemia (AML) with chemotherapy. The aim of this is to get the leukaemia into 
. This means there are no leukaemia cells in the blood or .
People in remission have regular tests and check ups. They have treatment to manage symptoms if they need to. Doctors call this best supportive care (BSC). It includes things such as:
- blood transfusions
- growth factors to increase the number of blood cells
- antibiotics to treat infections
But there is a risk that the leukaemia will come back. This is called recurrence.
In this trial, researchers wanted to find out if azacitidine tablets could help stop leukaemia coming back. When this trial was done, azacitidine was already being used for people with AML who weren’t able to have more intensive chemotherapy. This was usually through a drip into a vein.
The people taking part in this trial were all in complete remission. They were put into 1 of 2 groups at random:
- half had best supportive care and azacitadine tablets
- half had best supportive care and dummy (placebo) tablets
The main aims of the trial were to find out:
- if azacitidine tablets help stop AML coming back
- more about the side effects
- how having azacitidine affects people’s quality of life
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Andrew H. Wei and others
New England Journal of Medicine, 2020. Issue 383, pages 2526-2537
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Mike Dennis
Supported by
Celgene
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
